





Ticker	What they do	Other Notes	Links and Extra Info:
MMEDF	MindMed is a biotech psychedelic medicine company focused on the clinical development of LSD, Ibogaine, MDMA, DMT, and psilocybin for anxiety, depression, addiction, ADHD, and more.	Good longterm growth potential. Kevin O'Leary Buy-In	<a href="https://seekingalpha.com/article/4392873-mindmed-severely-undervalued-massive-upside-yet-to-come">https://seekingalpha.com/article/4392873-mindmed-severely-undervalued-massive-upside-yet-to-come</a>
RVVTF	Revive Therapeutics is a drug Developer who typically works with anti-inflammatory drugs. Acquired Psilocin Pharma Corp in Feb 2020. Currently working on dissolvable psilocybin strips. Could lead to good microdosing market potential in the future.	Currently also working on a drug that will help with lung inflammation in COVID-19 patients	<a href="https://www.forbes.com/sites/amandasiebert/2020/12/16/revive-therapeutics-the-psychedelics-company-working-on-a-covid-19-treatment/?sh=2f3625e71b05">https://www.forbes.com/sites/amandasiebert/2020/12/16/revive-therapeutics-the-psychedelics-company-working-on-a-covid-19-treatment/?sh=2f3625e71b05</a>
NUMI/LKYSF	The goal for Numinus Wellness is to allow access MDMA and psilocybin-assisted psychotherapy.	Recent changes in Canada are allowing NUMI to proceed with development of products and research involving MDMA and psilocybin assisted treatments.	<a href="https://www.newswire.ca/news-releases/numinus-wellness-commends-health-canada-for-its-intent-to-make-mdma-and-psilocybin-treatment-available-through-the-special-access-programme-858828809.html">https://www.newswire.ca/news-releases/numinus-wellness-commends-health-canada-for-its-intent-to-make-mdma-and-psilocybin-treatment-available-through-the-special-access-programme-858828809.html</a>
MYCOF	Mydecine Innovations Group is developing novel intellectual property around medicinal mushrooms and psychedelic medicines for the professional healthcare market. These guys just filed for seven new provisional patents and are working with regulatory companies for assistance in seeking FDA approval. This one may have some good potential.		<a href="https://www.financialbuzz.com/breaking-news-mydecine-innovations-group-shares-intellectual-property-update/">https://www.financialbuzz.com/breaking-news-mydecine-innovations-group-shares-intellectual-property-update/</a>
TRMNF	New Wave is one of the first Psilocybin companies to be established and publically traded. They have 3 key markets they focus on: Recreational, Mental Health, Natural Beauty products. They currently own mushroom cultivation farms in Jamaica with plans to expand upon future policy changes, etc.		<a href="https://newwavecorp.com/">https://newwavecorp.com/</a>
CMPS	The big one. These guys have buy-in from all over the industry at the moment. Currently focusing on a proprietary psilocybin formulation called COMP360 for treatment of depression, anxiety, etc.		<a href="https://investingnews.com/news/psychedelics-investing/compass-pathways-plc-to-participate-in-hc-wainwright-and-icr-investor-conferences/">https://investingnews.com/news/psychedelics-investing/compass-pathways-plc-to-participate-in-hc-wainwright-and-icr-investor-conferences/</a>
CLXPF	Cybin Inc., formerly Clarmin Explorations Inc., is a Canada-based life sciences company. The Company is focused on developing psychedelic pharmaceutical and non-psychedelic nutraceutical-based products. Its subsidiaries include Natures Journey Inc. and Serenity Life Sciences Inc. Serenity Life Sciences Inc. is focused on research and development of psilocybin-based medications. Natures Journey Inc. operates the Journey brand, which specializes in developing medicinal mushroom products. It has a drug delivery platform developed to administer psychedelic therapies and bypass liver metabolism. The Company also focus is on the development of treatment regimens consisting of psychedelic molecules and related clinical protocols.		<a href="https://www.businesswire.com/news/home/20210111005430/en/Cybin-Partners-with-Kernel-to-Leverage-its-Breakthrough-Neuroimaging-Technology-for-Psychedelic-Therapeutics">https://www.businesswire.com/news/home/20210111005430/en/Cybin-Partners-with-Kernel-to-Leverage-its-Breakthrough-Neuroimaging-Technology-for-Psychedelic-Therapeutics</a>





[1] Based on a potential 5 year return

[2] 5 year investment prediction

[3] 5 year investment prediction

[4] 3 month investment prediction

[5] 1 year forecast prediction

[6] Held on RH Lara + Chris shares

[7] 1 year investment forecast.

[8] 1 year investment.

[9] 1 year investment.

[10] 1 year investment